Sonder Capital Closes Futures II to Back the Next Wave of AI-Enabled Medtech and Robotics

Capital doesn’t whisper when conviction is involved. Sonder Capital just closed Futures II, and the signal cuts through clean if you know how to read between the lines. San Carlos is not exactly where you go for noise, which makes this move even cleaner. Kate Garrett, Fred Moll, Jay Watkins, and Colby Wood are not chasing headlines. They are placing calculated bets where precision matters and outcomes are measured in operating rooms, not pitch decks. Mayo Clinic and Sutter Health stepping in as LPs is not just capital showing up, it is frontline validation walking through the door with scrubs on.

The thesis cuts straight to it. AI enabled medical robotics and minimally invasive therapies are not science projects anymore. They are becoming the infrastructure for how care gets delivered when geography, staffing, and time decide to stop cooperating. Futures II is aimed directly at companies building those new care pathways and business models, especially in distributed settings where the old system starts to creak.

There is a certain discipline in backing what changes the standard of care instead of dressing up what already exists. Sonder Capital has been consistent about that since day one. Early stage, yes. But not early thinking. They position themselves as foundational investors, which sounds polite until you realize it means getting in before consensus, before comfort, before everyone else decides it was obvious.

And here is where it gets interesting for builders. When your cap table includes institutions like Mayo Clinic and Sutter Health, your feedback loop is not theoretical. It is clinical. Products do not just get built, they get stress tested against reality. That shortens the distance between idea and impact in a way most startups spend years trying to simulate.

The takeaway is not subtle. If you are building in medtech, diagnostics, or healthtech, the bar is rising toward solutions that shift where care happens, who delivers it, and how precise that care can be. Not marginal gains. Structural shifts.

Sonder Capital is leaning into that shift with Futures II, and the market tends to follow capital that knows exactly what it is doing, even when it does not feel the need to announce it too loudly.